Dexlan 30 mg (Capsule (Enteric Coated))

Indications

• Healing of Erosive Esophagitis
• Maintenance of Healed Erosive Esophagitis
• Symptomatic Non-Erosive Gastroesophageal Reflux Disease

Pharmacology

• Proton Pump Inhibitor (PPI)
• Suppresses Gastric Acid Secretion
• Specific Inhibition of (H+/K+)-ATPase
• R-enantiomer of Lansoprazole
• Dual Delayed Release (DDR) Formulation
• Plasma Concentration-time Profile

Dosage

• 30 mg Once daily for Maintenance of Healed Erosive Esophagitis and relief of heartburn
• 30 mg Once daily for Symptomatic Non-Erosive GERD
• 60 mg Once daily for Healing of Erosive Esophagitis
• Dosing Recommendations for Adults and Adolescents
• MUPS Dosing Recommendations

Administration

• Can be taken without regard to food
• Swallowed Whole
• Alternative Administration Method
• Guidelines for Missed Dose

Interaction

• Medicine Interaction
• Food and Other Interactions

Contraindications

• Known Hypersensitivity

Side Effects

• Diarrhea
• Abdominal Pain
• Nausea
• Vomiting
• Flatulence

Pregnancy & Lactation

• Pregnancy Category B
• No Adequate Studies in Pregnant Women
• No Adequate Studies in Lactating Mothers

Precautions & Warnings

• Gastric Malignancy
• Clostridium difficile Associated Diarrhea
• Bone Fracture
• Hypomagnesemia
• Concomitant Use with Methotrexate

Use in Special Populations

• Use in Children & Adolescents
• Safety and Effectiveness in Patients Below 12 Years
• Geriatric Use
• Renal Impairment
• Hepatic Impairment

Overdose Effects

• No Reports of Significant Overdose
• Effects of Multiple Doses
• Effects of Single High Dose

Therapeutic Class

• Proton Pump Inhibitor

Storage Conditions

• Temperature and Light Conditions
• Safety Precautions

Related Brands

• Dexilend 30 mg (Capsule (Enteric Coated)) - ziska-pharmaceuticals-ltd
• Dexilend 60 mg (Capsule (Enteric Coated)) - ziska-pharmaceuticals-ltd